The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer
Read More
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and…
Read More
A Phase III Trial of Stereotactic ablative radiotherapy for Oligometastatic Advanced Renal Carcinoma (SOAR)
Read More
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Read More
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2…
Read More
A Phase II Randomized Trial of Cabozantinib With or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Read More
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) (NCT# 05327686)
Read More
A phase 2 trial of ADT interruption in patients responding exceptionally to AR pathway inhibitor in metastatic hormone-sensitive prostate cancer (MHSPC): A-DREAM NCT #05241860
Read More
EA8191: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) (NCT04423211)
Read More
S1937: A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible…
Read More
S1931: PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL) (Study SWOG 1931) (NCT#0451059)
Read More
S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Read More
Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer).
Read More
GU011: A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN) (NCT# 05053152)
Read More
GU010: Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (NCT#05050084)
Read More
GU009: Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*) (NCT#04513717)…
Read More
GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (NCT #04134260)
Read More
EA8192: A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
Read More
Axitinib and Nivolumab in Treating Participants With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma
Read More
A032001: Testing the addition of the anti-cancer drug, cabozantinib, to the usual immunotherapy treatment, avelumab, in patients with metastatic urothelial cancer
Read More
A031801: A Phase II Randomized Trial of Radium-223 dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCaL)
Read More
A031702: A phase II study of Ipilimumab, CabOzantinib, and NIvolumab in rare genitourinary Cancers (ICONIC) (NCT03866382)
Read More
Gemcitabine Hydrochloride and Cisplatin in Treating Participants With Invasive Bladder Urothelial Cancer
Read More